Odanacatib - CAS# 603139-19-1 275 Specific inhibitors of the breast

Specific inhibitors of the breast cancer resistance protein (BCRP)

RGFP966 was dosed to mice at 10 mg/Kg once per day by subcutaneous dosing

EMCS Crosslinker

9(9):548-56

Treatment with U0126 efficiently reduces progeny virus titers of all tested strains in A549 cells

Odanacatib - CAS# 603139-19-1 275 Specific inhibitors of the breastOdanacatib, also known as MK 0822, CAS No. 603139 19 1, is an inhibitor of cathepsin K with potential anti osteoporotic activity. Odanacatib selectively binds to and inhibits the activity of cathepsin K, which may result in a reduction in bone resorption, improvement of bone mineral density, and a reversal in osteoporotic changes. Cathepsin K, a tissue specific cysteine protease that catalyzes degradation of bone matrix proteins such as collagen I II,